Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146956

Pw146956 View Pathway
drug action

Maralixibat Drug Metabolism Action Pathway

Homo sapiens

PW176087

Pw176087 View Pathway
metabolic

Maralixibat Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Maralixibat are predicted with biotransformer.

PW127558

Pw127558 View Pathway
drug action

Maraviroc Action Pathway

Homo sapiens
Maraviroc, known by the brand name Selzentry or Celsentri, is a chemokine receptor antagonist drug used to treat HIV-1 infections. It was developed by the drug company Pfizer. Maraviroc blocks HIV entry to the host cell by selectively binding to the human chemokine receptor (CCR5) present on the membrane of CD4 cells (T cells). This prevents the interaction of HIV-1 gp120 and CCR5 which is necessary for HIV to enter the cell and replicate.

PW145586

Pw145586 View Pathway
drug action

Maraviroc Drug Metabolism Action Pathway

Homo sapiens

PW176337

Pw176337 View Pathway
metabolic

Maraviroc Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW127766

Pw127766 View Pathway
drug action

Maribavir Action Pathway

Homo sapiens
Maribavir, known as the brand name Livtencity, is a benzimidazole riboside that inhibits cytomegalovirus (CMV) pUL97 kinase used to treat refractory post-transplant CMV infections. Human cytomegalovirus is a herpesvirus that is a common infection following stem cell or organ transplants. Like other herpesviruses, it tends to presist in the host and become reactivated under immunosuppressive conditions, such as during a transplant. Maribavir competitively inhibits human CMV pUL97 viral protein kinase which plays a role in viral egress, and viral replication or regulation of hot cell cycle progression. It has been found to participate in the acquisition of tegument during virion morphogenesis. It has also been found to phosphorylate the nuclear egress complex, which allows to viral release from the host cell. It also plays a role in the phosphorylation of Lamins-A/C and DNA polymerase. Lamin-A/C contributes to viral release with the nuclear egress complex, while DNA polymerase is essential in DNA replication. The inhibition of pUL97 viral protein kinase results in a viable, but severely defective virus upon replication. The exact reasons for this remain poorly defined.

PW145690

Pw145690 View Pathway
drug action

Maribavir Drug Metabolism Action Pathway

Homo sapiens

PW144310

Pw144310 View Pathway
drug action

Masoprocol Drug Metabolism Action Pathway

Homo sapiens

PW123643

Pw123643 View Pathway
metabolic

Mattinson photorespiration

Zea mays

PW146899

Pw146899 View Pathway
drug action

Mavacamten Drug Metabolism Action Pathway

Homo sapiens